

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2017 September 15; 9(9): 341-401





REVIEW

- 341 Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective
Finnerty BM, Gray KD, Moore MD, Zarnegar R, Fahey III TJ

ORIGINAL ARTICLE

Retrospective Cohort Study

- 354 Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade
Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF

- 363 Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers
Metcalfe RL, Al-Hadithi E, Hopley N, Henry T, Hodgson C, McGurk A, Mansoor W, Hasan J

Retrospective Study

- 372 *En bloc* pancreaticoduodenectomy and right hemicolectomy for locally advanced right-sided colon cancer
Kaneda Y, Noda H, Endo Y, Kakizawa N, Ichida K, Watanabe F, Kato T, Miyakura Y, Suzuki K, Rikiyama T

Prospective Study

- 379 Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer
Fiorentini G, Carandina R, Sarti D, Nardella M, Zoras O, Guadagni S, Inchingolo R, Nestola M, Felicioli A, Barnes Navarro D, Munos Gomez F, Aliberti C

CASE REPORT

- 385 Desmoid type fibromatosis: A case report with an unusual etiology
Jafri SF, Obaisi O, Vergara GG, Cates J, Singh J, Feedback J, Yandrapu H
- 390 Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a *CDKN2A* germline mutation carrier
Martínez de Juan F, Reolid Escribano M, Martínez Lapiedra C, Maia de Alcantara F, Caballero Soto M, Calatrava Fons A, Machado I
- 397 Cervical Castleman's disease mimicking lymph node metastasis of esophageal carcinoma
Yamabuki T, Ohara M, Kato M, Kimura N, Shirosaki T, Okamura K, Fujiwara A, Takahashi R, Komuro K, Iwashiro N, Hirano S

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Kimberly Maureen Brown, MD, Associate Professor, Surgical Patient Care Committee, St. Luke's Hospital, Kansas City, MO 6411, United States

AIM AND SCOPE

World Journal of Gastrointestinal Oncology (World J Gastrointest Oncol, WJGO, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGO covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Oncology is now indexed in Science Citation Index Expanded (also known as SciSearch[®]), PubMed, and PubMed Central.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Xin Kong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
 ISSN 1948-5204 (online)

LAUNCH DATE
 February 15, 2009

FREQUENCY
 Monthly

EDITORS-IN-CHIEF
Hsin-Chen Lee, PhD, Professor, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

Dimitrios H Roukos, MD, PhD, Professor, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktiro Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

EDITORIAL BOARD MEMBERS
 All editorial board members resources online at <http://www.wjgnet.com>

www.wjgnet.com/1948-5204/editorialboard.htm

EDITORIAL OFFICE
 Xiu-Xia Song, Director
World Journal of Gastrointestinal Oncology
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: editorialoffice@wjgnet.com
 Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive,
 Suite 501, Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: bpgoffice@wjgnet.com
 Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
 September 15, 2017

COPYRIGHT
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Cervical Castleman's disease mimicking lymph node metastasis of esophageal carcinoma

Takumi Yamabuki, Masanori Ohara, Mototsugu Kato, Noriko Kimura, Tomohide Shirosaki, Kunishige Okamura, Aki Fujiwara, Ryo Takahashi, Kazuteru Komuro, Nozomu Iwashiro, Satoshi Hirano

Takumi Yamabuki, Masanori Ohara, Tomohide Shirosaki, Kunishige Okamura, Aki Fujiwara, Ryo Takahashi, Kazuteru Komuro, Nozomu Iwashiro, Department of Surgery, National Hospital Organization Hakodate Hospital, Hakodate 041-8512, Japan

Mototsugu Kato, Department of Gastroenterology, National Hospital Organization Hakodate Hospital, Hakodate 041-8512, Japan

Noriko Kimura, Department of Pathology, National Hospital Organization Hakodate Hospital, Hakodate 041-8512, Japan

Satoshi Hirano, Department of Gastroenterological Surgery II, Hokkaido University Hospital, Sapporo 060-8648, Japan

Author contributions: Yamabuki T wrote the manuscript; Kimura N was in charge of the pathological diagnosis; Ohara M, Shirosaki T, Okamura K, Fujiwara A, Takahashi R, Komuro K and Iwashiro N participated in the medical care of the patient; Kato M and Hirano S served as the scientific advisor.

Institutional review board statement: This case report was approved by the ethics committee of National Hospital Organization Hakodate Hospital.

Informed consent statement: All study participants provided informed written consent prior to the treatment.

Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Takumi Yamabuki, MD, PhD, Department of Surgery, National Hospital Organization Hakodate Hospital, 18-16 Kawahara-cho, Hakodate 041-8512, Japan. bukiyama@themis.ocn.ne.jp
Telephone: +81-138-516281
Fax: +81-138-516288

Received: January 28, 2017

Peer-review started: February 9, 2017

First decision: March 22, 2017

Revised: April 6, 2017

Accepted: May 18, 2017

Article in press: May 19, 2017

Published online: September 15, 2017

Abstract

Castleman's disease (CD) is an uncommon benign lymphoproliferative disorder of unknown etiology. A rare case of cervical CD diagnosed at lymph node dissection for esophageal carcinoma is reported. An esophageal tumor was identified in a 67-year-old man during a follow-up examination after surgery for oral carcinoma. Esophagoscopy revealed a type 1 tumor in the cervical esophagus. Histology of esophagoscopy biopsies indicated squamous cell carcinoma. Contrast-enhanced computed tomography revealed swollen lymph nodes of the right cervical region. No distant metastasis was detected. Esophageal carcinoma, T2N2M0, Stage IIIA was diagnosed. Neoadjuvant chemotherapy was recommended, but the patient rejected the chemotherapy. The patient underwent laparoscopic-assisted transhiatal esophagectomy. The histopathological diagnosis was moderately differentiated squamous cell carcinoma with pT1bN0M0, Stage I A. On histology, the swollen lymph nodes of the right cervical region revealed CD. The patient's postoperative course was relatively good.

Key words: Castleman's disease; Lymph node metastasis; Esophageal carcinoma

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The association of Castleman's disease (CD) with epithelial malignancy is rare. To the best of our knowledge, the present case is the first report of a synchronous esophageal carcinoma and cervical CD. In the present case, we clinically diagnosed esophageal carcinoma with right cervical lymph nodes metastasis, T2N2M0, Stage IIIA preoperatively, but the stage was revised to pT1bN0M0, Stage I A on pathological diagnosis. *Via* histology, the swollen lymph nodes of the right cervical region revealed CD. This case demonstrates that cervical CD is rarely associated with an esophageal carcinoma and can clinically mimic nodal metastasis.

Yamabuki T, Ohara M, Kato M, Kimura N, Shirosaki T, Okamura K, Fujiwara A, Takahashi R, Komuro K, Iwashiro N, Hirano S. Cervical Castleman's disease mimicking lymph node metastasis of esophageal carcinoma. *World J Gastrointest Oncol* 2017; 9(9): 397-401 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v9/i9/397.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v9.i9.397>

INTRODUCTION

Castleman's disease (CD), which is otherwise known as angiofollicular hyperplasia of the lymph node, is a rare lymphoproliferative disorder that was first described in 1956 by Castleman *et al*^[1] as a benign proliferation of mediastinal lymphoid tissues of unknown etiology. CD most commonly develops in the mediastinum, and the cervical region is the second most common location. Clinically, CD manifests as localized disease (unicentric) or widespread disease (multicentric). The unicentric type of CD (UCD) typically presents as an asymptomatic single enlarged lymph node. By contrast, the multicentric type of CD (MCD) is associated with systemic symptoms, including hepatosplenomegaly, recurrent fevers, night sweats, and lymphadenopathy^[2]. The association or coexistence of an epithelial malignancy with CD is an exceptional occurrence. An extremely rare case presenting with synchronous cervical CD and esophageal carcinoma that clinically simulated nodal metastatic disease is reported, and the relevant literature is reviewed.

CASE REPORT

An esophageal tumor was identified in a 67-year-old man during a follow-up examination after surgery for oral carcinoma. He had comorbid disorders of hypertension, angina pectoris, diabetes mellitus, and hyperlipidemia. Enlarged lymph nodes in the right neck were palpable. Routine laboratory findings were unremarkable, with the exception of a slightly elevated serum squamous cell carcinoma (SCC)-related antigen




Figure 1 Esophagoscopy view of the tumor. Esophagoscopy reveals a type 1 tumor in the cervical esophagus.



Figure 2 Upper gastrointestinal barium study image. An upper gastrointestinal barium study reveals a 15-mm filling defect at the cervical esophagus.

(2.4 ng/mL, normal 0-1.5 ng/mL). Esophagoscopy revealed a type 1 tumor in the cervical esophagus (Figure 1). Histological examination of esophagoscopy biopsies revealed squamous cell carcinoma. An upper gastrointestinal barium study indicated a filling defect 15 mm in size at the cervical esophagus (Figure 2). Contrast-enhanced computed tomography (CT) revealed weakly enhanced swollen lymph nodes of the right cervical region (Figure 3). No distant metastasis was demonstrated. Esophageal carcinoma T2N2M0, Stage III A was diagnosed clinically. Neoadjuvant chemotherapy was recommended, but the patient rejected the chemotherapy. The patient underwent laparoscopic-assisted transhiatal esophagectomy with reconstruction using a posterior mediastinal gastric tube. The operative time was 265 minutes, and the amount of blood loss was 140 mL. Macroscopically, the type 1 tumor was located in the cervical esophagus, and it measured 30 mm × 15 mm (Figure 4). The histopathological diagnosis of the esophageal tumor was moderately differentiated squamous cell carcinoma (Figure 5A). In addition to the main tumor, numerous microscopic foci of squamous intraepithelial neoplasia from low grade to high grade were noted throughout the resected esophagus. No tumor metastases were present in the lymph nodes. However, three swollen lymph nodes



Figure 3 Preoperative computed tomography image. Contrast-enhanced computed tomography indicates weakly enhanced swollen lymph nodes in the right cervical region.



Figure 4 Surgical specimen of the esophagus. Macroscopically, the type 1 tumor is located in the cervical esophagus, and it measures 30 mm × 15 mm.

were identified in the right cervical region at #104. Histological examination of these lymph nodes revealed characteristic findings, such as tight concentric layering of lymphocytes at the periphery of the lymph follicles resulting in an onionskin appearance and inter-follicular diffuse proliferation of plasma cells. The findings were compatible with CD, plasma cell type (Figure 5B and C). The final diagnosis was esophageal squamous cell carcinoma without lymph node metastasis, pT1bN0M0, Stage I A and CD of the cervical lymph nodes. The patient had an uneventful postoperative course.

DISCUSSION

CD is an uncommon benign lymphoproliferative disorder of unknown etiology that was first reported by Castleman *et al*^[1] in 1956. A variant of the multicentric form was later found to be associated with human herpesvirus 8 (HHV-8), which is the same virus found in Kaposi's sarcoma. Similar to Kaposi's sarcoma, it is often identified in patients with human immunodeficiency virus (HIV)^[3]. From a systematic case review including 278 patients with unicentric CD (UCD), the main sites of disease are the chest (29%), neck (23%), abdomen (21%), and retroperitoneum (17%). In addition, other lymph node groups (axillary, inguinal) and the pelvis are also potential




Figure 5 Histopathological results of the resected specimen. A: The histopathological diagnosis of the resected esophagus is moderately differentiated squamous cell carcinoma (HE × 200); B: Histological examination of the right-sided neck lymph nodes reveals onionskin arrangement of small lymphocytes (HE × 20); C: Interfollicular diffuse proliferation of plasma cells (HE × 200).

sites of involvement^[4]. With advancements in the understanding of the disease entity, CD is classified into four subtypes: (1) hyaline-vascular CD; (2) plasma cell CD; (3) HHV-8-associated (plasmablastic) multicentric CD (MCD); and (4) MCD, not otherwise specified (NOS). The hyaline-vascular subtype is characterized by widened mantle zones composed of concentric rings of small lymphocytes in an "onion skin" pattern around small atrophic germinal centers with penetrating hyalinized vessels and dysplastic follicular dendritic cells^[3]. The subtype typically occurs as a unicentric process, involving a single node or local group of nodes. The plasma cell variety, which is characterized by sheets of mature plasma cells in the interfollicular tissue, occurs more often as a multicentric process^[5]. Patients with HHV-8-

associated (plasmablastic) MCD incur a unique risk of developing HHV-8-positive plasmablastic lymphoma^[6]. The multicentric NOS variant is a wastebasket term used to classify multicentric cases that are HHV-8 negative and/or those that exhibit intermediate histopathology (such as mixed features of both plasma cell and hyaline-vascular)^[7].

The radiographic characteristics of CD are non-specific, but some features could help raise suspicion for the diagnosis of CD. Plain radiographic findings include a mass effect. In addition, in approximately 30% of cases exhibit localized calcifications harboring a radial arrangement or star-shaped calcification, which is considered characteristic of CD. Ultrasonography (US) typically demonstrates a hypoechoic and homogeneous mass with a quite clear delimitation. CT scans reveal a solid, homogeneous, and well delimited mass that is enhanced with vascular contrast as a result of hypervascularity^[2].

A review of current therapeutic strategies for CD revealed that complete surgical resection is curative for UCD, leading to excellent long-term outcomes with 10-year overall survival rates in excess of 95%. Although the available literature is confined to a small number of cases, radiotherapy appears to be a reasonable alternative treatment option in unresectable cases of UCD. A range of systemic therapies has been used in MCD, including cytotoxic chemotherapy, antibodies directed against CD20 (rituximab) and interleukin-6 (IL-6) (siltuximab) and its receptor (tocilizumab), immunomodulators (interferon alpha, thalidomide, and lenalidomide), bortezomib, and antiviral agents (zidovudine and valganciclovir, ganciclovir, and cidofovir). Although these agents inhibit disease activity, the literature documenting their use is mainly confined to case reports or small series of patients, limiting overall assessment of efficacy and direct comparisons between regimens^[8].

CD is rarely associated with epithelial malignancy. Previously, five case reports observed the synchronous occurrence of carcinoma, two cases of pulmonary carcinoma^[9,10], two cases of squamous cell carcinoma of tongue^[11,12], and a thymic squamous cell carcinoma^[13]. To the best of our knowledge, the present case is the first report of a synchronous esophageal squamous cell carcinoma and a unicentric plasma cell type of CD.

IL-6 is related to the pathogenesis of CD in many patients^[14]. Several human tumors also secrete IL-6, including multiple myeloma^[15], renal cell carcinoma^[16], lung carcinoma^[17], cervical carcinoma^[18], and esophageal carcinoma^[19]. Furthermore, the serum IL-6 concentration is correlated with disease status and prognosis in esophageal squamous cell carcinoma^[19]. Although further studies are necessary to confirm this association, the present case suggests that IL-6 may serve as an important pathogenic link between CD and esophageal squamous cell carcinoma.

In the present case, the preoperative clinical diagnosis was esophageal carcinoma T2N2M0, Stage III

A, but the stage was revised to pT1bN0M0, Stage I A upon pathological diagnosis. The preoperative diagnosis of CD is very difficult given the lack of disease-specific signs. This case demonstrated that cervical CD could be rarely associated with an esophageal carcinoma when it clinically mimics nodal metastasis.

COMMENTS

Case characteristics

An esophageal tumor was identified in a 67-year-old man during a follow-up examination after surgery for oral carcinoma.

Clinical diagnosis

Enlarged lymph nodes in the right neck were palpable.

Differential diagnosis

Metastases from head and neck tumors, lymphoma, Kaposi sarcoma, bacterial infection, viral infection or tuberculous cervical lymphadenitis.

Laboratory diagnosis

Routine laboratory findings were unremarkable, with the exception of a slightly elevated serum squamous cell carcinoma-related antigen.

Imaging diagnosis

Esophagoscopy revealed a type 1 tumor in the cervical esophagus, and contrast-enhanced computed tomography indicated weakly enhanced swollen lymph nodes of the right cervical region.

Pathological diagnosis

The histopathological diagnosis of the esophageal tumor was moderately differentiated squamous cell carcinoma, and histological examination of cervical lymph nodes revealed Castleman's disease, plasma cell type.

Treatment

The patient underwent laparoscopic-assisted transhiatal esophagectomy with cervical lymph node dissection.

Related reports

Castleman's disease is rarely associated with epithelial malignancy. Previously, five case reports observed the synchronous occurrence of carcinoma: two cases of pulmonary carcinoma, two cases of squamous cell carcinoma of tongue, and a thymic squamous cell carcinoma.

Term explanation

Castleman's disease is an uncommon benign lymphoproliferative disorder of unknown etiology. The main sites of disease were the chest, neck, abdomen, and retroperitoneum.

Experiences and lessons

This case demonstrates that cervical Castleman's disease can be rarely associated with an esophageal carcinoma when it clinically mimics nodal metastasis.

Peer-review

This is an interesting case report demonstrating that swollen lymph nodes during preoperative tumor staging can be due to other uncommon benign diagnoses.

REFERENCES

- 1 **Castleman B**, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. *Cancer* 1956; **9**:

- 822-830 [PMID: 13356266]
- 2 **Bucher P**, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal Castleman's disease. *World J Surg Oncol* 2005; **3**: 33 [PMID: 15941478 DOI: 10.1186/1477-7819-3-33]
 - 3 **Cronin DM**, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. *Adv Anat Pathol* 2009; **16**: 236-246 [PMID: 19546611 DOI: 10.1097/PAP.0b013e3181a9d4d3]
 - 4 **Talat N**, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. *Ann Surg* 2012; **255**: 677-684 [PMID: 22367441 DOI: 10.1097/SLA.0b013e318249dcdc]
 - 5 **Keller AR**, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. *Cancer* 1972; **29**: 670-683 [PMID: 4551306]
 - 6 **Dupin N**, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. *Blood* 2000; **95**: 1406-1412 [PMID: 10666218]
 - 7 **Hill AJ**, Tirumani SH, Rosenthal MH, Shinagare AB, Carrasco RD, Munshi NC, Ramaiya NH, Howard SA. Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. *Br J Radiol* 2015; **88**: 20140670 [PMID: 25710283 DOI: 10.1259/bjr.20140670]
 - 8 **Chan KL**, Lade S, Prince HM, Harrison SJ. Update and new approaches in the treatment of Castleman disease. *J Blood Med* 2016; **7**: 145-158 [PMID: 27536166 DOI: 10.2147/JBM.S60514]
 - 9 **Higashikuni Y**, Mori M, Kino H. Interleukin-6-producing giant cell carcinoma of the lung with multicentric Castleman's disease-like presentation. *Intern Med* 2007; **46**: 669-673 [PMID: 17527041 DOI: 10.2169/internalmedicine.46.6003]
 - 10 **Horio H**, Hijima T, Sakaguchi K, Kuwabara K. Mediastinal Castleman disease associated with pulmonary carcinoma, mimicking N2 stage lung cancer. *Jpn J Thorac Cardiovasc Surg* 2005; **53**: 286-289 [PMID: 15952326 DOI: 10.1007/s11748-005-0044-4]
 - 11 **Deshmukh M**, Bal M, Deshpande P, Jambhekar NA. Synchronous squamous cell carcinoma of tongue and unicentric cervical Castleman's disease clinically mimicking a stage IV disease: a rare association or coincidence? *Head Neck Pathol* 2011; **5**: 180-183 [PMID: 21240573 DOI: 10.1007/s12105-011-0240-8]
 - 12 **Pereira TC**, Landreneau R, Nathan G, Sturgis CD. Pathologic quiz case. Large posterior mediastinal mass in a young woman. Pathologic diagnosis: localized hyaline-vascular-type Castleman disease (angiofollicular lymphoid hyperplasia). *Arch Pathol Lab Med* 2001; **125**: 964-967 [PMID: 11419989 DOI: 10.1043/0003-9985(2001)125<0964:PQCLPM>2.0.CO;2]
 - 13 **Matsumura N**, Shiiki H, Saito N, Uramoto H, Hanatani M, Nonaka H, Nakamura S. Interleukin-6-producing thymic squamous cell carcinoma associated with Castleman's disease and nephrotic syndrome. *Intern Med* 2002; **41**: 871-874 [PMID: 12413013 DOI: 10.2169/internalmedicine.41.871]
 - 14 **Dispenzieri A**, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM. The clinical spectrum of Castleman's disease. *Am J Hematol* 2012; **87**: 997-1002 [PMID: 22791417 DOI: 10.1002/ajh.23291]
 - 15 **Kawano M**, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. *Nature* 1988; **332**: 83-85 [PMID: 3258060 DOI: 10.1038/332083a0]
 - 16 **Miki S**, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. *FEBS Lett* 1989; **250**: 607-610 [PMID: 2787758 DOI: 10.1016/0014-5793(89)80805-1]
 - 17 **Matsuguchi T**, Okamura S, Kawasaki C, Shimoda K, Omori F, Hayashi S, Kimura N, Niho Y. Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplification and increased mRNA stability. *Eur J Haematol* 1991; **47**: 128-133 [PMID: 1716216 DOI: 10.1111/j.1600-0609.1991.tb00135.x]
 - 18 **Takano H**, Harigaya K, Ishii G, Sugaya Y, Soeta S, Nunoyama T, Shirasawa H, Shimizu K, Tokita H, Simizu B, Mikata A, Sekiya S. Interleukin-6 (IL-6) production in carcinoma of the cervix. *Arch Gynecol Obstet* 1996; **258**: 25-33 [PMID: 8789430 DOI: 10.1007/BF01370929]
 - 19 **Oka M**, Yamamoto K, Takahashi M, Hakozaiki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T, Suzuki T. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. *Cancer Res* 1996; **56**: 2776-2780 [PMID: 8665513]

P- Reviewer: Reeh M S- Editor: Gong ZM L- Editor: A
E- Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

